TOP > 外国特許検索 > MUCOSAL VACCINE

MUCOSAL VACCINE 実績あり

外国特許コード F120006532
整理番号 S2010-0682-C0
掲載日 2012年5月8日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2011JP054586
国際公開番号 WO 2011108521
国際出願日 平成23年3月1日(2011.3.1)
国際公開日 平成23年9月9日(2011.9.9)
優先権データ
  • 特願2010-045205 (2010.3.2) JP
発明の名称 (英語) MUCOSAL VACCINE 実績あり
発明の概要(英語) Disclosed is a mucosal vaccine which is characterized by comprising: (a) an AD vehicle that comprises a lipid and a synthetic peptide which comprises the amino acid sequence of KnLm (wherein n represents a number of 4-8 and m represents a number of 11-20); (b) a carboxyvinyl polymer; and (c) an antigen protein in such an amount that does not produce, by itself, mucosal immunity IgA and blood immunity IgG in such amounts that effective immune induction and protection against the infection can be achieved. The mucosal vaccine is also characterized by producing antigen-specific mucosal immunity IgA and blood immunity IgG in such amounts that effective immune induction and protection against the infection can be achieved. The mucosal vaccine has higher antibody producing ability than conventional mucosal vaccines, and is thus capable of achieving excellent effects with an extremely small amount of antigen.
従来技術、競合技術の概要(英語) BACKGROUND ART
And 2 is Patent Document 1, the conventional inactivated vaccines or the like that the disadvantages of the toxoid, such as immune adjuvants and mucosal vaccine development of current has been described in detail.
These Patent Documents 1, as described in 2, such as conventional intramuscular subcutaneously inoculated into from a vaccine, is the root of a natural infection of the virus to induce the production of the antibody IgA mucosa of switching to the mucosal vaccine need, wider and deeper recognized. In particular, as the next generation vaccine 21 st century, the production of antibodies IgA, inducing an immune response or mucosal local immune, so-called mucosal vaccine development and practical use is possible for the deficiencies of all over the world, has not been achieved yet.
The present inventors to solve this problem, and/or pulmonary surfactant C B and lung surfactant, a lipid and a complex of antigen and drug vehicle (AD), from this AD vehicle mucosal vaccine antigen, and filed a patent application (Patent Document 1) are. Further the present inventors have found, and the amount of the antigen (V) vehicle AD (A) the amount of the weight ratio of V/A by adjusting the size, the specific production and selection of antibodies IgA IgA, both IgG antibody production and found that can be converted to, the mechanism of action of this mucosal vaccine and filed a patent (Patent Document 2). These patents Document 1, is 2, a fragment of a lung surfactant C B and the validity of the (peptide) is disclosed.
Further the present inventors have, for various variants of pulmonary surfactant fragment antibody production enhancing effect as a result of studies, Patent Document 1, a partial peptide disclosed in 2 smaller in size than that in spite of a peptide, a potentiation or a strong induction of antibody production, in particular, production of secretory IgA antibodies alone, the, both IgG and secretory IgA antibody production in the blood that has superior effective guidance has the effect of synthetic peptide KnLm (however n is 4-8, m is 11-20) and the vehicle components AD, this AD vehicle with antigen from the mucosal vaccine, and filed a patent application (Patent Document 3) are.
In addition, take the same route of administration of mucosal vaccine is a nasal, increase the viscosity thereof, hay fever or allergy to continuously in order to demonstrate the efficacy of carboxyvinyl polymer (CVP) hydroxypropyl cellulose (HPC) or other widely used, including other sodium alginate thickening gelling agent is used. For example, containing HPC (Patent Document 4) or mucosal vaccine, vaccine formulations containing mucosal application type CVP (Patent Document 5) influenza vaccine and intranasal spray administration (Patent Document 6) and the like are also known. In addition, the patent document 7, antigen, adjuvant particularly Poly (I.C.) and thickener (sodium alginate and the like) is made of a vaccine for mucosal administration disclosed.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • TOKUSHIMA UNIVERSITY
  • 発明者(英語)
  • KIDO Hiroshi
  • MIZUNO Dai
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LA LC LK LR LS LT LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PE PG PH PL PT RO RS RU SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ MD RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
ご興味のある方は、下記「問合せ先」へ電子メールまたはFAXでご連絡ください。

PAGE TOP

close
close
close
close
close
close